Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Vlatka Smoljanovic, S Gally, Pascale Tomasini, Adam Gondos, Stefan Hammerschmidt, Gracy Crane, Nasreen Khan, Nuria Lara
Publikováno v:
Lung Cancer. 149:144-153
Objectives Quantify the burden of central nervous system (CNS) metastases on health-related quality of life (HRQoL) and healthcare resource use (HRU) in patients with advanced non-small-cell lung cancer (NSCLC) from a prospective European study in cl
Autor:
Michael Millward, Sanjeevan Muruganandan, Wei Sen Lam, J. Spiro, Sukanya Arunachalam, Aron Chakera, Y. C. Gary Lee, Catherine A. Read, Mary S. Attia, Anna K. Nowak, Fred K. Chen, Wee Loong Chin, Kevin Murray, Jenette Creaney
Publikováno v:
Lung Cancer. 140:87-92
Objectives Currently, there is no optimal salvage therapy for patients with malignant pleural mesothelioma (MPM) who relapse after treatment with first-line chemotherapy. In line with the strong preclinical rationale for targeting fibroblast growth f
Publikováno v:
Lung Cancer. 136:37-44
Purpose The purpose of this study was to elucidate the clinicopathologic and lymph node metastatic characteristics in patients with adenocarcinoma manifested as persistent ground glass mass (GGM, ground glass opacity [GGO] exceeding 3 cm in diameter)
Autor:
Seonghae Yoon, Hoon Gu Kim, Jae Yong Cho, Ji Youn Han, Eun Kyung Cho, Byoung Chul Cho, Jin-Soo Kim, Kyung Hee Lee, Ho Jung An, Jong Seok Lee, Jin Hyoung Kang, Keunchil Park, Dae Ho Lee, Ka Young Hong, Dong Wan Kim, Ki Hyeong Lee, Bong Seog Kim, In Jin Jang, Oak Pil Han, Young Joo Min, Young Su Noh
Publikováno v:
Lung Cancer. 135:66-72
Objectives The aim of this phase 1/2 study was to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of olmutinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who had fail
Publikováno v:
Lung Cancer. 127:90-95
Objectives Previous studies have suggested that poor oral health might increase the risk of lung cancer among European- and Asian- descendants. The association has not been investigated among African Americans or socially disadvantaged populations. I
Autor:
Irene Karampela, Gerasimos Socrates Christodoulatos, Ioanna Marinou, Georgios Antonakos, Evaggelos Vogiatzakis, Maria Dalamaga, George P. Sotiropoulos, Marianna Kotopouli, Athanasios G. Papavassiliou, Antigoni Lekka
Publikováno v:
Lung Cancer. 125:291-299
Chemerin is an emerging adipocytokine at the intersection of inflammation, chemotaxis, thrombosis, fibrinolysis and metabolism. Our aims were 1) to explore circulating chemerin in resectable non-small cell lung cancer (NSCLC) taking into account its
Autor:
Amita Patnaik, Harry Raftopoulos, James Chih-Hsin Yang, Shirish M. Gadgeel, Leena Gandhi, Matthew A. Gubens, Vassiliki A. Papadimitrakopoulou, Lecia V. Sequist, Ralph Hauke, Robert Bachman, Hossein Borghaei, James P. Stevenson, Liza C. Villaruz, Sanatan Saraf, Corey J. Langer
Publikováno v:
Lung Cancer. 125:273-281
Objectives Platinum-based chemotherapy for advanced non–small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021 (Clinicaltrials.gov,
Autor:
Carlos Alvarez, Ana Belén Enguita, Julio Sánchez de Cos, Roldán Cortés, Luis Seijo, Cristina Balcells, Eduard Monsó, Esther Barreiro, Marta Cascante, Anabel Martinez-Romero, Ramon Rami-Porta, Laura Millares
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
instname
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients diagnosed in early stage and surgically-treated have five-year mortality rate >20%. The identification of biomarkers able to predict progression and death may help to identify patients needing
Publikováno v:
Lung Cancer. 122:1-6
Background Avitinib is an oral, potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for the EGFR T790 M mutation. We report the safety, intra-/extracranial efficacy, and the blood–brain barrier (BBB) pen
Autor:
Zhehai Wang, Yi Luo, Kai Li, Weiqiang Chen, Baolan Li, Yinlan Chen, Yin Cheng, Xiaoyan Si, Hanping Wang, Faguang Jin, Jianhua Shi, Jianying Zhou, Xiuwen Wang, Xiaotong Zhang, Li Zhang, Donglin Wang, Jianxing He, Mengzhao Wang, Kejun Nan, Yuankai Shi, Baohui Han, Qiming Wang
Publikováno v:
Lung Cancer. 122:32-37
Objectives Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall